Trial Profile
Focused Ultrasound Therapy to Augment Antigen Presentation and Immune-Specificity of Checkpoint Inhibitor Therapy With Pembrolizumab in Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Sep 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Pharmacodynamics
- Acronyms Breast-48
- 07 Sep 2022 Status changed from recruiting to discontinued.
- 29 Oct 2020 Planned primary completion date changed from 16 Sep 2020 to 16 Sep 2021.
- 08 May 2019 Planned primary completion date changed from 16 Sep 2019 to 16 Sep 2020.